Jim Simons Oric Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

$56.7 Billion
Q2 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 47,000 shares of ORIC stock, worth $484,100. This represents 0.0% of its overall portfolio holdings.

Number of Shares

47,000

Previous 110,900 57.62%

Holding current value

$484,100

Previous $1.53 Million 78.23%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$6.63 - $12.93 $423,657 - $826,227	-63,900 Reduced 57.62%	47,000 $332,000
Q1 2024 May 13, 2024	SELL	$8.04 - $16.03 $623,903 - $1.24 Million	-77,600 Reduced 41.17%	110,900 $1.53 Million
Q4 2023 Feb 13, 2024	SELL	$5.41 - $9.43 $1.03 Million - $1.8 Million	-191,300 Reduced 50.37%	188,500 $1.73 Million
Q3 2023 Nov 14, 2023	BUY	$6.05 - $9.28 $218,405 - $335,008	36,100 Added 10.5%	379,800 $2.3 Million
Q2 2023 Aug 11, 2023	SELL	$4.95 - $8.4 $1,980 - $3,360	-400 Reduced 0.12%	343,700 $2.67 Million
Q1 2023 May 12, 2023	BUY	$4.26 - $6.75 $116,298 - $184,275	27,300 Added 8.62%	344,100 $1.96 Million
Q4 2022 Feb 13, 2023	SELL	$2.41 - $5.89 $203,886 - $498,294	-84,600 Reduced 21.08%	316,800 $1.87 Million
Q3 2022 Nov 14, 2022	SELL	$3.15 - $5.24 $146,377 - $243,497	-46,469 Reduced 10.38%	401,400 $1.28 Million
Q2 2022 Aug 12, 2022	BUY	$2.7 - $7.07 $617,676 - $1.62 Million	228,769 Added 104.41%	447,869 $2.01 Million
Q1 2022 May 13, 2022	BUY	$4.54 - $16.1 $875,312 - $3.1 Million	192,800 Added 733.08%	219,100 $1.17 Million
Q4 2021 Feb 11, 2022	BUY	$12.01 - $20.3 $315,863 - $533,890	26,300 New	26,300 $387,000

Others Institutions Holding ORIC

# of Institutions

118

Shares Held

63.1M

Call Options Held

Put Options Held

View Full List

About Oric Pharmaceuticals, Inc.

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $408M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

More about ORIC

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account